Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.

BMC cancer - 11 Aug 2005

Mesquita Bárbara, Veiga Isabel, Pereira Deolinda, Tavares Ana, Pinto Isabel M, Pinto Carla, Teixeira Manuel R, Castedo Sérgio

Abstract excerpt

BACKGROUND: The mechanisms of chemoresistance in ovarian cancer patients remain largely to be elucidated. Paclitaxel/cisplatin combination is the standard chemotherapeutic treatment for this disease, although some patients do not respond to therapy. Our goals were to investigate whether TUBB mutations and mismatch repair defects underlie paclitaxel and cisplatin resistance. METHODS: Thirty-four patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Base Pair Mismatch

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to DNA Replication

Share to Drug Resistance, Neoplasm

Share to Ovarian Neoplasms

Share to Paclitaxel

Share to Tubulin

Source

Open in PubMed Open full text

Identifiers

PMID: 16095531
DOI: 10.1186/1471-2407-5-101
PMCID: PMC1199587

Genes

TUBB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.PMID 16095531Read ↗

Class III β-Tubulin Overexpression Is a Prominent Mechanism of Paclitaxel Resistance in Ovarian Cancer PatientsSemantic proximity Read ↗

Taxol Resistance Among the Different Histological Subtypes of Ovarian Cancer May Be Associated With the Expression of Class III β-TubulinSemantic proximity Read ↗

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.Semantic proximity Read ↗

Mutational analysis of the class I β‐tubulin gene in human breast cancerSemantic proximity Read ↗

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.Semantic proximity Read ↗

Do beta-tubulin mutations have a role in resistance to chemotherapy?Semantic proximity Read ↗

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.Semantic proximity Read ↗

Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.Semantic proximity Read ↗

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.Semantic proximity Read ↗

Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer.Semantic proximity Read ↗

Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer.Semantic proximity Read ↗

Absence of beta-tubulin gene mutation in gastric carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.